Novo Nordisk held its Capital Markets Day this week to outline an ambitious plan for future growth as the company faces patent expirations for its blockbuster Wegovy and Ozempic treatments in key markets during the early 2030s. The company proposed a pipeline of potential blockbuster products designed to diversify beyond obesity and diabetes, but Wall Street reacted negatively to the presentation. Investors expressed concern that the projected growth targets matched industry averages rather than exceeding them, and they criticized the lack of clarity regarding near-term recovery plans. The stock experienced significant selling pressure following the announcement.
Meanwhile, Eli Lilly has been steadily expanding its market share in the GLP-1 space, including in the emerging oral weight loss category. Lilly’s obesity pill Foundayo is gaining traction in the United States, with one-third of new GLP-1 pill patients adopting the drug. The company has also established an early advantage in the Medicare obesity drug market following federal coverage that began in July. According to Lilly’s leadership, approximately 70% of the 700,000 seniors who started GLP-1 treatments through Medicare selected Lilly’s products. In the broader U.S. GLP-1 market during the second quarter, Lilly controlled approximately 61% share compared to Novo’s 39%.
Novo CEO Mike Doustdar expressed confidence that patients may prefer oral formulations over injections, suggesting that pills could represent a larger portion of the market by decade’s end. However, industry analysts note that Lilly possesses significant competitive advantages, including superior commercial resources and manufacturing capabilities. Foundayo, classified as a small-molecule drug, can be produced at scale more easily and cost-effectively than Novo’s peptide-based Wegovy pill. Additionally, Lilly’s pipeline includes advanced candidates such as retatrutide, a triple-agonist drug expected to demonstrate enhanced weight loss, with regulatory approval sought in the first quarter of 2027.
Novo is investing substantially in manufacturing infrastructure with the goal of expanding capacity to serve ten times more patients by 2030. The company launched a higher-dose version of Wegovy this year to close the efficacy gap with Lilly’s offerings. Analysts project that competition in the GLP-1 market will remain intense, with Lilly maintaining its leadership position while Novo attempts to recover from recent operational challenges and regain momentum in the market it originally helped pioneer.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI